SG Americas Securities LLC Boosts Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)

SG Americas Securities LLC lifted its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 20.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,315 shares of the company’s stock after acquiring an additional 4,715 shares during the quarter. SG Americas Securities LLC owned 0.05% of 2seventy bio worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of TSVT. Exchange Traded Concepts LLC increased its holdings in 2seventy bio by 114.7% in the third quarter. Exchange Traded Concepts LLC now owns 25,838 shares of the company’s stock valued at $101,000 after buying an additional 13,802 shares during the last quarter. Deutsche Bank AG increased its holdings in 2seventy bio by 15.7% in the third quarter. Deutsche Bank AG now owns 26,134 shares of the company’s stock valued at $102,000 after buying an additional 3,537 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in 2seventy bio by 112.6% in the third quarter. Public Employees Retirement System of Ohio now owns 84,757 shares of the company’s stock valued at $332,000 after buying an additional 44,895 shares during the last quarter. Graham Capital Management L.P. increased its holdings in 2seventy bio by 195.0% in the third quarter. Graham Capital Management L.P. now owns 75,891 shares of the company’s stock valued at $297,000 after buying an additional 50,166 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in 2seventy bio by 4.0% in the third quarter. Wellington Management Group LLP now owns 2,994,471 shares of the company’s stock valued at $11,738,000 after buying an additional 114,549 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Stock Performance

Shares of TSVT opened at $4.64 on Friday. 2seventy bio, Inc. has a fifty-two week low of $1.53 and a fifty-two week high of $12.69. The company has a market capitalization of $238.08 million, a price-to-earnings ratio of -1.05 and a beta of 1.84. The firm has a 50-day simple moving average of $5.21 and a 200-day simple moving average of $4.01.

2seventy bio (NASDAQ:TSVT) last announced its earnings results on Tuesday, March 5th. The company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.11. 2seventy bio had a negative net margin of 216.73% and a negative return on equity of 59.19%. The business had revenue of $10.68 million during the quarter, compared to the consensus estimate of $13.91 million. During the same quarter in the prior year, the firm earned ($0.60) earnings per share. Equities research analysts forecast that 2seventy bio, Inc. will post -1.39 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on TSVT shares. TD Cowen reissued a “market perform” rating on shares of 2seventy bio in a report on Wednesday, January 31st. Wedbush reaffirmed a “neutral” rating and set a $5.00 price objective on shares of 2seventy bio in a report on Monday, March 18th. Citigroup raised their price objective on 2seventy bio from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, April 8th. SVB Leerink raised 2seventy bio from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $5.00 to $18.00 in a report on Wednesday, January 31st. Finally, Leerink Partnrs raised 2seventy bio from a “market perform” rating to an “outperform” rating in a report on Wednesday, January 31st. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, 2seventy bio currently has an average rating of “Hold” and an average price target of $13.17.

Insider Transactions at 2seventy bio

In other 2seventy bio news, Director Casdin Capital, Llc bought 300,000 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was acquired at an average price of $4.90 per share, for a total transaction of $1,470,000.00. Following the completion of the purchase, the director now owns 1,482,623 shares of the company’s stock, valued at $7,264,852.70. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.60% of the company’s stock.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.